Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure

By afschroeder • September 20, 2025

Green L, Armstrong A, Han G, Jacobson A. Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure. Dermatol Ther (Heidelb). 2025 Sep 19. doi: 10.1007/s13555-025-01533-9. Epub ahead of print. PMID: 40971026.

Tags: Biologic failure, Dermatology, ixekizumab, Publications, Quality of Life, Refractory, secukinumab, Therapy switching, tnf inhibitor

Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma

Robatel S, Hillen H, Mutisheva I, Müller JC, Wartenberg M, Ma F, Bäriswyl L, Evenepoel J, Scheele CLGJ, Lee DJ, Modlin RL, Kessler U, Nobis[...]

Association between out-of-pocket costs and treatment patterns in psoriasis and psoriatic arthritis: A claims-based cohort study

Roberts AM, Jeong C, Chou P, Ma EJ, Katz A, Yan MJ, Johnsen N, Nong Y, Armstrong AW. Association between out-of-pocket costs and treatment patterns[...]

Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias

Issa T, Klomhaus AM, Kasakevich C, Pickford J, Goh C. Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias. JAAD[...]